MAM
Misleading ad gives wrong notions about blood donation: Health Ministry
NEW DELHI: Despite a letter to the Advertising Standards Council of India (ASCI) by the Health Ministry, an advertisement that can potentially mislead blood donors is still running on air.
The advertisement has been put out by carwale.com – which sells used cars or car parts – and attempted to prove that the need for exactness in demand. The ad shows a doctor talking to someone on the phone for more blood for a patient. He says if you do not have more units of ‘A’, then send ‘AB’ type, and saying 19-20 ka farak hai (just a minor difference). The aim of the commercial is to say that there has to be exactness in what the customer wants.
The Health Ministry has taken objection to the commercial as it creates doubts in the minds of the donors.
The National AIDS Control Board, which is expected to check every blood sample for AIDS, has written to ASCI to ensure that the advertisement is pulled off air as it does not meet ASCI’s standards of honest representations.
Under Indian laws, human blood is treated as a ‘drug’ under the Drugs & Cosmetics (D&C) Act. During the HIV/AIDS crisis, the Indian government made it mandatory for any donated blood to be tested for HIV 1&2 antibodies, giving the Blood Safety Programme to NACO.
ASCI secretary-general Shweta Purandare told media that a decision on the complaint had not been taken yet. “We usually do not speak about individual complaints. In this case, we haven’t conveyed our final decision to the Ministry,” she said.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
